Navigation Links
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Date:6/13/2013

tal Sciences in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford, and steering committee member for the study.

A copy of the EULAR oral presentation can be accessed at:  2013 EULAR - JADA 52-Week Presentation  

Trial DesignThis randomized, open-label, long-term extension of Phase 2b JADA study included 201 (95 percent) of the eligible 212 patients. Of the 201 patients, 184 completed 52 weeks of treatment, 15 discontinued treatment, and two patients had not yet completed the full 52 weeks of treatment. Patients received either 4 mg or 8 mg once-daily doses of baricitinib beginning at week 24 through week 52.

In the initial 12-week treatment duration, patients received one of four doses of baricitinib (1 mg, 2 mg, 4 mg or 8 mg) or placebo, administered once daily. In the 12- to 24-week portion of the study, patients initially randomized to placebo or the 1 mg baricitinib dose were re-randomized to receive either 4 mg once daily or 2 mg twice daily for an additional 12 weeks; patients initially randomized to the 2 mg, 4 mg and 8 mg doses continued therapy with those doses.

Patients who completed week 24 were eligible to receive either the 4- or 8-mg once daily dose through week 52. The study is ongoing, with all patients who are continuing in the study receiving baricitinib 4 mg once daily.

About JAK InhibitionThere are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.[3] These enzymes are critical components of signaling mechanisms used by a number of cytokines and growth factors, including several that are elevated in patients with RA. Cytokines such as interleukin-6, -12 and -23 and both type 1 and type 2 interferons signal through these pathways. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoi
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lilly to Present at Goldman Sachs Global Healthcare Conference
2. Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimers Disease Research and Development
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
5. Todays Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals
6. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
7. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
8. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
9. Neogen announces Bohannon retirement, successor named
10. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
11. Hemostemix Announces Formation of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Diasome Pharmaceuticals, Inc. ( http://www.diasome.com ) has received ... States patent has recently been allowed for the Company’s ... “Lipid Construct for Delivery of Insulin to a Mammal,” ... the use of Diasome’s proprietary Hepatocyte Directed Vesicles (“HDV”) ... effectively reach the liver’s metabolic cells, called hepatocytes. , ...
(Date:3/30/2015)... PMG Research, Benchmark Research, and Miami ... of VaxCorps, a network of highly experienced, geographically ... of vaccine trials in healthy adult, elderly, and ... conducted over 500 phase I-III vaccine clinical trials, ... as well as a vast array of other ...
(Date:3/30/2015)... , March 30, 2015  NuGene International, Inc. ... corporation, NuGene BioPharma, Inc. has added another internationally ... Dr. Guan is an internationally recognized researcher in ... college education at Peking University, China ... from the University of North Carolina, Chapel Hill. ...
(Date:3/30/2015)... 2015 CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announced ... has approved the Company,s application to conduct a Phase ... (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
Breaking Biology Technology:Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5
... to Stop the Spread of Pancreatic ... ... Ph.D., executive,vice president and chairman of the Pharmaceutical Research Institute (PRI),at Albany ... National Cancer Institute, part of the National Institutes,of Health. Dr. Mousa along ...
... 2008 Earnings Conference Call Tuesday, July 29, 2008, 5:00 ... p.m. U.S. EDT, FRAZER, Pa., June 26 ... results for 5:00 p.m. EDT on Tuesday, July 29, 2008., , ... July 29, 2008 Schedule 4:10 p.m. EDT ...
... NEEDHAM, Massachusetts, June 26 ,Oridion Systems Ltd. ... developer,and manufacturer of innovative capnography monitoring solutions, ... Award from IMDA, the,association of medical specialty ... acknowledges the Company,s achievements in market development,and ...
Cached Biology Technology:Albany College of Pharmacy Researcher Receives $368,445 Grant from the National Institutes of Health 2Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributor's Association 2Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributor's Association 3Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributor's Association 4
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/2/2015)... 2, 2015  Businesses have a new option ... Tharon Rankins Enterprises has announced the launch of ... way for businesses to protect their customers, personal ... Beconux is a biometric transaction processing ... similarly to an ATM machine, the new system ...
(Date:2/24/2015)... YORK , Feb. 24, 2015 This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Personal Data Protection Company Launches New Product 2World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11
... at UT Southwestern Medical Center are among an elite group ... find biomarkers for lung cancer that develops in people who ... Research Network (EDRN) and the Canary Foundation, a nonprofit organization ... funding of $1 million each for the first year of ...
... the gene involved in regulating serotonin and norepinephrine in ... adults with developmental and intellectual disabilities, new research indicates. ... issue of the American Journal on Intellectual and ... http://tinyurl.com/mw8baj . "Problem behaviors in these populations account ...
... Plata/Leipzig. Increasing numbers of children around the world are ... attacks. Although the key external causes of these diseases ... air pollution), it had not previously been possible to ... have a targeted impact on them. Researchers at the ...
Cached Biology News:$2 million grant aids study of lung cancer in people who never smoked 2$2 million grant aids study of lung cancer in people who never smoked 3Genetic marker linked to problem behaviors in adults with developmental disabilities 2When children have breathing problems 2When children have breathing problems 3
Mouse Aminopeptidase P2/XPNPEP2 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
... 53 new primer sets added in Dec ... than 3 hours , Detection from ... , Specific primers available for hundreds ... either real-time or end-point RT-PCR , ...
AGAROSE PREP, 50G, 1 EA. Category: Genephor Precast Gels....
in vitro Translation, Accessory Products...
Biology Products: